In Malawi, 236 participants from the Advancing Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericin B plus flucytosine was associated with the lowest 1 year mortality (27.5% [95% confidence interval, 16.3 to 44.1]).
Keywords: HIV; Malawi; cryptococcal meningitis; long-term follow-up; treatment.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.